Abstract:Background Stratal dopamine depletion contributes to both motor and non-motor symptoms of patients with Parkinson’s disease (PD). The objective of current study is to explore whether stratal dopamine depletion shapes clinical heterogeneity by impairing brain networks of PD patients. Methods In this cross-sectional study, PD participants undergoing functional magnetic resonance imaging from Parkinson’s Progression Markers Initiative (PPMI) database were investigated. According to the levels of striatal binding ratio (SBR) in bilateral striatum, PD patients were classified into lower quartile group (SBR level rank: 0%∼25%), interquartile group (SBR level rank: 26%∼75%), and upper quartile group (SBR level rank: 76%∼100%) based on their SBR level quartiles to examine how stratal dopamine depletion affects clinical manifestations and brain networks. Findings PD patients in the lower quartile group showed more severe motor and non-motor symptoms compared to upper quartile group. Additionally, topological metrics in both structural and functional network were significantly different between upper quartile group and lower quartile group. Furthermore, the functional network of left primary motor cortex (M1) was specifically impaired in lower quartile group, which resulted in topological disruptions in functional network. Importantly, impaired left M1 network in PD patients mediated the effects of striatal dopamine depletion on both motor and non-motor symptoms. Interpretation Striatal dopamine depletion specifically impaired left M1 network, which contributed to aberrant functional network topology and dopamine-dependent motor and non-motor symptoms. Funding National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai (Grant No. NRCTM(SH)-2021-03). ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Committee of all participating sites approved the PPMI study. The informed consents have been signed by all study participants, which can be obtained from the site investigators. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All the raw data used in the preparation of this Article were downloaded from PPMI database ([www.ppmi-info.org/data][1]).All data produced in the present study are available upon reasonable request to the authors. [1]: http://www.ppmi-info.org/data

Decline in striatal binding ratio associated with accelerated decline in performance on Symbol Digit Modality but not MoCA in Parkinson's disease psychosis

Parkinson's disease psychosis associated with accelerated multidomain cognitive decline

Parkinson’s disease psychosis associated with accelerated multi-domain cognitive decline

Progressive Brain Atrophy in Parkinson's Disease Patients Who Convert to Mild Cognitive Impairment.

Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.

Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment

Convergence of striatal monoaminergic degeneration and CSF A beta 42/alpha-synuclein reductions in human Parkinson's disease with possible cognitive decline

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Striatal and peripheral dopaminergic alterations related to cognitive impairment in patients with schizophrenia

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease

Lateralisation of Striatal Function: Evidence from 18F-Dopa PET in Parkinson's Disease.

Exploring the Distinct Effect of Age at Onset and Caudate Denervation on Cognitive Deficits in Early Parkinson's Disease

[Clinical and neuropsychological features and changes to regional cerebral blood flow in ‍patients with Parkinson's disease dementia]

Striatal Dopamine Depletion Drives Disease Progression and Network Topology Aberrations Specifically by Impairing Left M1 Network

Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease

Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

Metabolite Changes in Prefrontal Lobes and the Anterior Cingulate Cortex Correlate with Processing Speed and Executive Function in Parkinson Disease Patients

Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease

Epigenetic and cognitive signatures of striatal DAT binding among healthy elderly individuals

White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease: results from the Ontario Neurodegenerative Diseases Research Initiative